Shionogi Adds to Its Rare Disease Strategy With $2B IntraBio Acquisition

Shionogi’s IntraBio acquisition brings Aqneursa, a drug accepted for treating two uncommon neurological issues and the potential to broaden to extra indications, each uncommon and customary. It’s Shionogi’s second large uncommon illness transfer this yr, following the acquisition of world rights to an amyotrophic lateral sclerosis drug from Tanabe Pharma.

The submit Shionogi Provides to Its Uncommon Illness Technique With $2B IntraBio Acquisition appeared first on MedCity Information.

Source link